Journal of veterinary internal medicine · 2025
Treatment With Remdesivir Alone or in Combination With GS-441524 in Cats With Ocular Involvement of Feline Infectious Peritonitis: An Observational Case Series.
СтатьяObservational Study, VeterinaryНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Andrews Amy L M M, Izaguirre Eneko, Green Jodie, Scurrell Emma, Gogova Savina, Tayler Sarah, Kafarnik Christiane
Аннотация
BACKGROUND: Remdesivir and GS-441524 have successfully treated cats with feline infectious peritonitis (FIP) but the changes in associated signs of ocular disease are not reported.
OBJECTIVE: Evaluate the response of FIP-associated signs of ocular disease before and after treatment with remdesivir, GS-441524, or both.
ANIMALS: Sixty-one cats diagnosed with FIP by the Internal Medicine services between October 2021 and December 2022 that were treated with injectable, oral, or a combination of anti-viral therapies were reviewed.
METHODS: Observation study. Signalment, associated signs of ocular disease, treatment, outcome, and follow-up of affected cats were analyzed.
RESULTS: Associated signs of ocular disease in cats with FIP were diagnosed in 33% (20/61) cats, with a median follow-up of 55 days (IQR 47.3-90.8, range: 16-1071 days) in 11 cats with FIP. Ocular changes were all associated with uveitis, of which 20% (4/20) had anterior uveitis, 25% (5/20) had posterior uveitis, and 55% (11/20) had panuveitis. Ocular disease occurred in effusive (11/20; 55%) and non-effusive (9/20; 45%) FIP and was bilateral in 70% (14/20) cats. All cats started an 84-day course of treatment, with the majority (17/20; 85%) receiving remdesivir in the initial period. Of those, 70% (12/17) received a high dose of 15-20 mg/kg/day. Eleven cats with uveitis had long-term follow-up nine (9/11; 82%) of these had resolution of uveitis. Eighty-seven percent (13/15) of cases with anterior uveitis received topical anti-inflammatory medication. Eighty percent (16/20) of cats survived.
CONCLUSION AND CLINICAL IMPORTANCE: Cats with FIP commonly have ocular involvement. Associated uveitis responded to remdesivir or GS-441524 treatment effectively in 82% of cases.
OBJECTIVE: Evaluate the response of FIP-associated signs of ocular disease before and after treatment with remdesivir, GS-441524, or both.
ANIMALS: Sixty-one cats diagnosed with FIP by the Internal Medicine services between October 2021 and December 2022 that were treated with injectable, oral, or a combination of anti-viral therapies were reviewed.
METHODS: Observation study. Signalment, associated signs of ocular disease, treatment, outcome, and follow-up of affected cats were analyzed.
RESULTS: Associated signs of ocular disease in cats with FIP were diagnosed in 33% (20/61) cats, with a median follow-up of 55 days (IQR 47.3-90.8, range: 16-1071 days) in 11 cats with FIP. Ocular changes were all associated with uveitis, of which 20% (4/20) had anterior uveitis, 25% (5/20) had posterior uveitis, and 55% (11/20) had panuveitis. Ocular disease occurred in effusive (11/20; 55%) and non-effusive (9/20; 45%) FIP and was bilateral in 70% (14/20) cats. All cats started an 84-day course of treatment, with the majority (17/20; 85%) receiving remdesivir in the initial period. Of those, 70% (12/17) received a high dose of 15-20 mg/kg/day. Eleven cats with uveitis had long-term follow-up nine (9/11; 82%) of these had resolution of uveitis. Eighty-seven percent (13/15) of cases with anterior uveitis received topical anti-inflammatory medication. Eighty percent (16/20) of cats survived.
CONCLUSION AND CLINICAL IMPORTANCE: Cats with FIP commonly have ocular involvement. Associated uveitis responded to remdesivir or GS-441524 treatment effectively in 82% of cases.